fbpx

Navigating Vaping Reforms

New Safety Standards for Therapeutic Vaping Products Take Effect 1 July 2025

On 19 June 2025, the TGA published a statement regarding new standards for nicotine vaping products from July 2025, which contains additional information for pharmacists ahead of 1 July 2025. From 1 July 2025, pharmacies may only supply products that comply with these strengthened standards.

 

Pharmacists should continue to consult the TGA notified vape list to identify compliant products.

 

To prepare for the changes, pharmacies should:

 

  • Review vapes product inventory: review your inventory to identify any vape products that do not meet the strengthened products standards.
  • Remove non-compliant vaping products: remove these products from your inventory. From 1 July 2025, they can no longer be sold or supplied.
  • Return or dispose: return non-compliant products to the supplier or follow proper disposal procedures as per local regulations.
  • Educate staff: ensure pharmacy staff are aware of the strengthened product standards, product compliance and availability, and alternative brands.
  • Inform patients: Communicate with consumers and prescribers about the changes to vaping product standards, and available products.

2025 Workshop registration now available

This interactive workshop equips pharmacists with the knowledge and practical skills to identify, manage, and treat nicotine dependence. Using a harm minimisation framework, you will explore behavioural support, pharmacotherapy options, and patient-centred strategies to reduce the health risks of smoking and vaping. .

REGISTER FOR WORKSHOP
Do you need help navigating the new vaping reforms?
Access free support from a Senior Pharmacist via the Pharmacist Advice Line.
MORE INFORMATION ON PHARMACIST ADVICE LINE

The Therapeutic Goods and Other Legislation Amendment (Vaping Reforms) Act 2024, introduces significant changes to vaping regulations. 

 

Vapes containing nicotine or zero-nicotine substances will require a prescription until 30 September 2024, with supply restricted to pharmacies. From 1 October 2024, vaping products with nicotine concentrations of 20 mg/mL or less can be supplied without a prescription, subject to pharmacist assessment and guidance. From 1 October 2024, a prescription will still be required for patients wishing to access a vape greater than 20mg/mL or for a patient aged under 18 years. 

 

Pharmacists will play a pivotal role in supplying therapeutic vapes and offering guidance on managing nicotine dependence and harm reduction strategies. It is anticipated that pharmacists may face increased demand for managing nicotine dependence and from consumers who use vapes recreationally.

 

The Pharmaceutical Society of Australia is facilitating a series of webinars and interactive workshops to help pharmacists to understand their obligations and support pharmacists to deliver treatment of nicotine dependence in this new model of care.

 

New CPD module for pharmacists delivering nicotine dependence treatment under vaping reforms
REGISTER NOW FOR MODULE
Cover image of Nicotine dependence support guidelines
ACCESS THE NICOTINE DEPENDENCE SUPPORT GUIDELINES
DOWNLOAD NICOTINE DEPENDENCE SUPPORT GUIDELINES
STATE & TERRITORY REGULATIONS - SUPPLY OF THERAPEUTIC VAPES

Navigating Vaping Reforms – Webinars

This series of three expert-led webinars will empower pharmacists with comprehensive knowledge and practical guidance on navigating legislative changes, including their evolving role in providing nicotine cessation therapy and vaping cessation guidance.

 

This series aims to equip pharmacists with insights into the public health impacts of the reforms, clarify ethical and liability considerations in prescribing and dispensing vapes, and outline PSA’s strategic plan for supporting pharmacists adapt to this new model of care over the next 12 months. 

 

Webinar #1: Navigating the new vaping regulations, what they mean for you

WATCH THE RECORDING OF WEBINAR 1

Webinar #2: Best practices for managing therapeutic vape requests in pharmacies 

WATCH THE RECORDING OF WEBINAR 2

Webinar #3: Balancing vaping ethics and legal duty – Key insights for you 

WATCH THE RECORDING OF WEBINAR 3

Navigating Vaping Reforms – Interactive Workshops 

From 1 October 2024, therapeutic vapes with a nicotine concentration of 20mg/mL or less will be available in pharmacies to patients 18 years or over without a prescription. Pharmacists will need to be satisfied if it is clinically appropriate, and meet several other conditions, to supply a vape to a patient without a prescription. These changes will help facilitate patient access while maintaining appropriate controls and protections.

 

There’s currently no therapeutic vapes approved by TGA and included on the Australian Register of Therapeutic Goods (ARTG).  Unapproved vapes still have unclear safety and efficacy profiles. As medicines experts, pharmacists are well-positioned to educate the community around evidence-based approaches for smoking cessation and managing nicotine dependence. It’s also essential pharmacists are across these regulatory changes relating to supplying therapeutic vapes, where legitimate patient access to therapeutic vapes are required. 

 

The learning objectives for this workshop are:  

  1. Demonstrate effective communication with the patient, prescriber and any others involved in the management of the patient.   
  2. Discuss ethical and professional responsibilities, particularly considering the current lack of evidence supporting the therapeutic benefits of nicotine vaping products.   
  3. Apply knowledge of legislation and risk assessment, management and mitigation process requirements regarding the nicotine vaping reforms. 

Registration is free but spaces are limited. 

ENROL NOW IN A WORKSHOP

Management options for smoking or vaping cessation – Online module

Nicotine dependence remains a significant public health challenge in Australia, with smoking and vaping contributing to preventable morbidity and mortality. Pharmacists are uniquely positioned to provide accessible, evidence-based support for smoking and vaping cessation, including pharmacological and non-pharmacological management. Understanding the assessment of nicotine dependence, recognising withdrawal symptoms, and knowing when to refer patients to medical practitioners or support services are critical to optimising patient outcomes. This training ensures pharmacists can confidently manage these responsibilities.

 

1 hour module – 2 Group 2 CPD credits

ENROL NOW IN MODULE

Prescribing and dispensing workflow resources

PSA has developed two pharmacist workflow resources that are a quick reference of the key steps involved in prescribing and dispensing therapeutic vapes with links to more detailed information in the PSA guidelines or on the TGA website.

 

  • Pharmacist workflow for prescribing and dispensing therapeutic vapes for smoking cessation and nicotine dependence – (S3). This workflow applies when prescribing and dispensing therapeutic vapes under the TGA Special Access Scheme Category C (SAS-C) pathway. 
Image of S3 resource
DOWNLOAD PRESCRIBING AND DISPENSING THERAPEUTIC VAPES RESOURCE
  • Pharmacist workflow for dispensing therapeutic vapes. This workflow is applicable when dispensing to a patient with a prescription.
Image of Dispensing resource
DOWNLOAD DISPENSING THERAPEUTIC VAPES RESOURCE

Need help with submitting SAS C S3/S4 notifications?

Watch the videos below which provide step-by-step instructions.

 

SAS C S3 Nicotine Submission user guide – Pharmacists

SAS C S4 Nicotine Submission user guide – Health practitioners

Frequently Asked Questions

Do I need to register?

Yes, spaces are limited and registration is essential using the links above. 

Will the webinars and workshops be recorded?

The webinars will be recorded and made available on our website for those unable to attend. The workshops will only be available in person. 

I am not a member of the PSA – can I still attend?

Yes, this training is funded by the Australian Government funded and is available for members and non-members of the Pharmaceutical Society of Australia. 

Should I attend both the webinars and the workshops?

You may choose to attend either or both. Webinars and workshops complement each other but are designed to be valuable independently. 

Are CPD points available?

Yes, participants are eligible for Group 2 CPD points.

How much does it cost to attend?

There is no cost to attend. The training is fully funded by the Australian Government. 

Can students attend?

Pharmacy students are eligible to attend the webinars only. 

What if I have questions or concerns about vaping reforms?

During the webinars and workshops, there will be opportunities to ask questions and discuss your concerns with the speakers. You can also reach out to PSA directly for additional support.

Can I attend a workshop in a different state if the timing/location is more convenient for me?

Yes, pharmacists are welcome to attend workshops in any state or region, as long as space is available.

In the spirit of reconciliation, the Pharmaceutical Society of Australia (PSA) acknowledges the Traditional Custodians of Country throughout Australia and their connections to land, sea and community. We pay our respect to their Elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today. We recognise that Aboriginal and Torres Strait Islander peoples were our first pharmacists.

CONTACT US | TERMS OF USE | PRIVACY

© 2025 Pharmaceutical Society of Australia Ltd. All rights reserved.